Prolactinomas, cabergoline, and pregnancy

Imagem de Miniatura
Arquivos
art_GLEZER_Prolactinomas_cabergoline_and_pregnancy_2014.PDF (184.5 KB)
Citações na Scopus
49
Tipo de produção
article
Data de publicação
2014
Editora
HUMANA PRESS INC
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
ENDOCRINE, v.47, n.1, p.64-69, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Hyperprolactinemia, frequently caused by a prolactinoma, is an important cause of infertility among young women. Dopamine agonists (DA) are the treatment of choice. Although cabergoline (CAB) is currently considered the gold standard DA, bromocriptine (BRC) remains the drug of choice for women desiring pregnancy, as it was proven to be safe in more than 6,000 pregnancies. The purpose of this review is to perform a critical evaluation of CAB safety in pregnancy, as it is used by most patients harboring prolactinomas. Although the number of CAB-induced pregnancies (about 800) is still reduced as compared with those under BRC treatment, data in the literature do not point to increase risk of preterm delivery or fetal malformations, comparing to pregnancies induced by BRC and those in the general population. Moreover, CAB use throughout pregnancy was reported in about ten cases, without evidence of any harm to fetal development. Therefore, even though BRC still remains the recommended DA drug for pregnancy induction or use during pregnancy in women with prolactinomas, increasing evidences point to the safety of CAB for this purpose.
Palavras-chave
Hyperprolactinemia, Prolactinoma, Infertility, Pregnancy, Dopamine agonist, Cabergoline
URI
https://observatorio.fm.usp.br/handle/OPI/9190
Referências
  1. Araujo-Lopes R, 2014, ENDOCRINOLOGY, V155, P1010, DOI 10.1210/en.2013-1889
  2. Auriemma RS, 2013, J CLIN ENDOCR METAB, V98, P372, DOI 10.1210/jc.2012-3039
  3. Bajwa Sukhwinder Kaur, 2011, Indian J Endocrinol Metab, V15 Suppl 3, pS267, DOI 10.4103/2230-8210.84883
  4. Banerjee A, 2009, CLIN ENDOCRINOL, V70, P812, DOI 10.1111/j.1365-2265.2008.03425.x
  5. Beltrame D, 1996, REPROD TOXICOL, V10, P471, DOI 10.1016/S0890-6238(96)00134-7
  6. Bronstein Marcello Delano, 2005, Pituitary, V8, P31, DOI 10.1007/s11102-005-5083-4
  7. Casanueva FF, 2006, CLIN ENDOCRINOL, V65, P265, DOI 10.1111/j.1365-2265.2006.02562.x
  8. Chiodini I, 2003, J ENDOCRINOL INVEST, V26, P96
  9. Colao A, 2008, CLIN ENDOCRINOL, V68, P66, DOI 10.1111/j.1365-2265.2007.03000.x
  10. Del Pozo E., 1984, ENDOCRINE EFFECT DOP, P191
  11. Forsbach-Sánchez Gerardo, 2009, Rev Med Inst Mex Seguro Soc, V47, P307
  12. Glezer A, 2012, J CLIN ENDOCR METAB, V97, P2211, DOI 10.1210/jc.2011-2976
  13. Herlenius E, 2004, EXP NEUROL, V190, pS8, DOI 10.1016/j.expneurol.2004.03.027
  14. Hurault-Delarue C., 2014, ARCH GYNECOL OBSTET, V23, P586
  15. Jones J., 1997, Journal of Obstetrics and Gynaecology (Abingdon), V17, P375
  16. JONES TH, 1994, BRIT J OBSTET GYNAEC, V101, P349, DOI 10.1111/j.1471-0528.1994.tb13626.x
  17. Krupp P., 1988, 2 WORD C GYN OBST RI
  18. Laloi-Michelin M, 2007, INT J GYNECOL OBSTET, V99, P61, DOI 10.1016/j.ijgo.2007.04.027
  19. Lebbe M, 2010, CLIN ENDOCRINOL, V73, P236, DOI 10.1111/j.1365-2265.2010.03808.x
  20. Liu C, 2001, Pituitary, V4, P179, DOI 10.1023/A:1015319007880
  21. Mancini T, 2008, ENDOCRIN METAB CLIN, V37, P67, DOI 10.1016/j.ecl.2007.10.013
  22. Melmed S, 2011, J CLIN ENDOCR METAB, V96, P273, DOI 10.1210/jc.2010-1692
  23. Molitch ME, 2011, BEST PRACT RES CL EN, V25, P885, DOI 10.1016/j.beem.2011.05.011
  24. Ono M, 2010, J CLIN ENDOCR METAB, V95, P2672, DOI 10.1210/jc.2009-2605
  25. Ricci E, 2002, REPROD TOXICOL, V16, P791, DOI 10.1016/S0890-6238(02)00055-2
  26. Robert E, 1996, REPROD TOXICOL, V10, P333, DOI 10.1016/0890-6238(96)00063-9
  27. Salvatori R, 2014, ENDOCRINE, V47, P725, DOI 10.1007/s12020-014-0281-3
  28. Shahzad Hira, 2012, BMC Res Notes, V5, P606, DOI 10.1186/1756-0500-5-606
  29. Sonigo C, 2012, J CLIN INVEST, V122, P3791, DOI 10.1172/JCI63937
  30. Stalldecker G, 2010, PITUITARY, V13, P345, DOI 10.1007/s11102-010-0243-6
  31. SUNDSTROM E, 1993, DEV BRAIN RES, V75, P1, DOI 10.1016/0165-3806(93)90059-J
  32. Tamburrano G., 1994, J ENDOCRINOL INVE S1, V14, P104
  33. Verhelst J, 1999, J CLIN ENDOCR METAB, V84, P2518, DOI 10.1210/jc.84.7.2518
  34. Webster J., 1994, NEW ENGL J MED, V331, P942

Coleções
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - HC/ICHC